A Phase 2a Multicenter, Randomized, Double-blind, Placebo-controlled Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, of HBI-002, an Oral Low-dose Carbon Monoxide (CO) Liquid Drug Product, Administered Daily Over 14 Days in Subjects With Parkinson's Disease (PD)

Inclusion Criteria: Subjects must meet the following criteria before being enrolled into the study: 1. Signed informed consent. 2. Male or female 40-80 years of age 3. Non-smoker for at least 5 years with smoking defined as the use of smoked products (e.g. tobacco, marijuana, vaping or other) 4. No smoking in the home (i.e. not living with a smoker) 5. Body weight between 60 kg and 110 kg (inclusive) and with BMI less than 30 kg/m2 at screening and baseline 6. Diagnosis of PD according to the Movement Disorder Society within 60 months of screening 7. Hoehn and Yahr stage ≤ 3 8. PD therapy: u…